TY - JOUR
T1 - Immunoglobulin for myasthenia gravis
AU - Alzuabi, Muayad A.
AU - Manolopoulos, Apostolos
AU - Elmashala, Amjad
AU - Odabashian, Roupen
AU - Naddaf, Elie
AU - Murad, M. Hassan
N1 - Publisher Copyright:
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
PY - 2020/12/5
Y1 - 2020/12/5
N2 - Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. To assess the effects of immunoglobulin in adults and children with acute exacerbation or worsening of myasthenia gravis (MG), or with chronic stable generalized MG. Specifically, we will investigate: 1) intravenous immunoglobulin (IVIg) compared to subcutaneous immunoglobulin (SCIg), and 2) immunoglobulin administered via either route (irrespective of treatment duration, dosage, and regimen) compared to no treatment, placebo, acetylcholinesterase inhibitors, plasma exchange, corticosteroids, or other immunosuppressive therapy.
AB - Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. To assess the effects of immunoglobulin in adults and children with acute exacerbation or worsening of myasthenia gravis (MG), or with chronic stable generalized MG. Specifically, we will investigate: 1) intravenous immunoglobulin (IVIg) compared to subcutaneous immunoglobulin (SCIg), and 2) immunoglobulin administered via either route (irrespective of treatment duration, dosage, and regimen) compared to no treatment, placebo, acetylcholinesterase inhibitors, plasma exchange, corticosteroids, or other immunosuppressive therapy.
UR - http://www.scopus.com/inward/record.url?scp=85102996079&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85102996079&partnerID=8YFLogxK
U2 - 10.1002/14651858.CD013801
DO - 10.1002/14651858.CD013801
M3 - Article
AN - SCOPUS:85102996079
SN - 1465-1858
VL - 2020
JO - Cochrane Database of Systematic Reviews
JF - Cochrane Database of Systematic Reviews
IS - 12
M1 - CD013801
ER -